Skip to Main Content (Press Enter)

Logo UNISS
  • ×
  • Home
  • Corsi
  • Insegnamenti
  • Professioni
  • Persone
  • Pubblicazioni
  • Strutture
  • Terza Missione
  • Competenze

Logo UNISS

|

UNIFIND

uniss.it
  • ×
  • Home
  • Corsi
  • Insegnamenti
  • Professioni
  • Persone
  • Pubblicazioni
  • Strutture
  • Terza Missione
  • Competenze
  1. Pubblicazioni

Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study

Articolo
Data di Pubblicazione:
2019
Citazione:
Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study / Casula, Milena; Paliogiannis, Panagiotis; Ayala, Fabrizio; De Giorgi, Vincenzo; Stanganelli, Ignazio; Mandalà, Mario; Colombino, Maria; Manca, Antonella; Sini, Maria Cristina; Caracò, Corrado; Ascierto, Paolo Antonio; Satta, Rosanna Rita; Dedola, Mf; Denti, S; Fedeli, Ma; Montesu, Ma; Profili, S; Scotto, T; Sini, G; Tanda, F; Lissia, Amelia; Cossu, Antonio; Palmieri, Giuseppe; Ghiorzo, P; Queirolo, P; Quaglino, P; Botti, G; Sileni, Vc; Di Giacomo, Am. - In: BMC CANCER. - ISSN 1471-2407. - 19:1(2019), p. 772. [10.1186/s12885-019-5984-7]
Abstract:
Introduction Multiple primary melanomas (MPM) occur up to 8% of patients with cutaneous malignant melanoma (CMM). They are often sporadic harbouring several somatic mutations, but also familial cases harbouring a CDKN2A germline mutation have been describe in Caucasian populations. The aim of this study was to investigate the incidence, the distribution patterns and the impact of known and unknown germline and somatic mutations in patients with MPM from Italy. Materials and methods One-hundred and two MPM patients were enrolled for germline mutation analysis, and five patients with at least four MPMs were identified for somatic mutation analysis. The demographic, pathologic and clinical features were retrieved from medical records. Molecular analysis for both germline and somatic mutations was performed in genomic DNA from peripheral blood and tissue samples, respectively, through a next generation sequencing approach, using a specific multiple-gene panel constructed by the Italian Melanoma Intergroup for somatic analysis and a commercial cancer hotspot panel for somatic analysis. Results CDKN2A mutations were detected in 6/16 (37.5%) and 3/86 (3.5%) MPM cases with and without family history for melanoma, respectively. Furthermore, multiple MC1R and, to a lesser extent, ATM variants have been identified. BAP1 variants were found only in MPM patients from southern Italy. The most frequent somatic variants were the pathogenic BRAF(V600E) and TP53, followed by KIT, PIK3CA, KDR, and NRAS. Single APC, ERBB4, MET, JAK3 and other variants with unknown function were also detected. Conclusions CDNK2A mutation is the most relevant susceptibility mutation in Italian patients with MPM, especially those with a family history for CMM. The prevalence of this mutation and other sequence variants identified in this study varies among specific sub-populations. Furthermore, some heterogeneity in driver somatic mutations between sporadic MPMs has been observed, as well as in a number of associated sequence variants the clinical impact of which needs to be further elucidated.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
BRAF; CDKN2A; Cancer; Melanoma; Mutations; NGS; Skin
Elenco autori:
Casula, Milena; Paliogiannis, Panagiotis; Ayala, Fabrizio; De Giorgi, Vincenzo; Stanganelli, Ignazio; Mandalà, Mario; Colombino, Maria; Manca, Antonella; Sini, Maria Cristina; Caracò, Corrado; Ascierto, Paolo Antonio; Satta, Rosanna Rita; Dedola, Mf; Denti, S; Fedeli, Ma; Montesu, Ma; Profili, S; Scotto, T; Sini, G; Tanda, F; Lissia, Amelia; Cossu, Antonio; Palmieri, Giuseppe; Ghiorzo, P; Queirolo, P; Quaglino, P; Botti, G; Sileni, Vc; Di Giacomo, Am
Autori di Ateneo:
COLOMBINO Maria
COSSU Antonio Giuseppe Maria
MONTESU Maria Antonia
PALIOGIANNIS Panagiotis
PALMIERI Giuseppe
SATTA Rosanna Rita
Link alla scheda completa:
https://iris.uniss.it/handle/11388/227648
Pubblicato in:
BMC CANCER
Journal
  • Utilizzo dei cookie

Realizzato con VIVO | Designed by Cineca | 26.5.1.0